share_log

Insider Buying: Aura Biosciences, Inc. (NASDAQ:AURA) Director Purchases $123,700.00 in Stock

Insider Buying: Aura Biosciences, Inc. (NASDAQ:AURA) Director Purchases $123,700.00 in Stock

内幕买入：Aura Biosciences, Inc.（纳斯达克股票代码：AURA）董事购买了123,700.00美元的股票
Defense World ·  2022/12/18 05:51

Aura Biosciences, Inc. (NASDAQ:AURA – Get Rating) Director David Michael Johnson bought 10,000 shares of Aura Biosciences stock in a transaction that occurred on Thursday, December 1st. The stock was bought at an average price of $12.37 per share, for a total transaction of $123,700.00. Following the completion of the acquisition, the director now directly owns 15,000 shares of the company's stock, valued at $185,550. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink.

奥拉生物科学公司(纳斯达克代码：AURA-GET评级)董事David迈克尔·约翰逊在12月1日星期四的一笔交易中购买了10,000股奥拉生物科学公司的股票。这只股票的平均价格为每股12.37美元，总成交额为123,700.00美元。收购完成后，董事现在直接拥有15,000股该公司股票，价值185,550美元。此次收购是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可在以下网址获得此超链接.

Aura Biosciences Trading Up 1.8 %

AURA生物科学公司股价上涨1.8%

Shares of AURA stock opened at $12.17 on Friday. The business's 50 day simple moving average is $12.96 and its 200 day simple moving average is $14.20. Aura Biosciences, Inc. has a one year low of $11.29 and a one year high of $24.83.

AURA股票周五开盘报12.17美元。该业务的50日简单移动均线切入位为12.96美元，200日简单移动均线切入位为14.20美元。Aura Biosciences，Inc.的一年低点为11.29美元，一年高位为24.83美元。

Get
到达
Aura Biosciences
奥拉生物科学
alerts:
警报：

Aura Biosciences (NASDAQ:AURA – Get Rating) last announced its earnings results on Thursday, November 10th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.01). As a group, equities analysts anticipate that Aura Biosciences, Inc. will post -2.02 EPS for the current year.

奥拉生物科学(纳斯达克：AURA-GET评级)最近一次公布财报是在11月10日(周四)。该公司公布本季度每股收益(0.53美元)，低于普遍预期的(0.52美元)和(0.01美元)。作为一个整体，股票分析师预计奥拉生物科学公司本年度每股收益将为2.02欧元。

Hedge Funds Weigh In On Aura Biosciences

对冲基金对Aura Bioscions的看法

Several institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp lifted its stake in Aura Biosciences by 25.5% in the third quarter. Bank of New York Mellon Corp now owns 50,336 shares of the company's stock valued at $912,000 after buying an additional 10,240 shares during the period. BNP Paribas Arbitrage SNC acquired a new position in Aura Biosciences in the third quarter valued at approximately $105,000. State Street Corp lifted its stake in Aura Biosciences by 16.2% in the third quarter. State Street Corp now owns 298,438 shares of the company's stock valued at $5,408,000 after buying an additional 41,692 shares during the period. Vanguard Group Inc. lifted its stake in Aura Biosciences by 39.2% in the third quarter. Vanguard Group Inc. now owns 605,884 shares of the company's stock valued at $10,978,000 after buying an additional 170,709 shares during the period. Finally, BlackRock Inc. lifted its stake in Aura Biosciences by 14.3% in the third quarter. BlackRock Inc. now owns 1,013,455 shares of the company's stock valued at $18,363,000 after buying an additional 126,732 shares during the period. 53.96% of the stock is owned by institutional investors and hedge funds.
几家机构投资者最近增持或减持了该公司的股份。纽约梅隆银行(Bank Of New York Mellon Corp)在第三季度将其在Aura Biosciences的持股增加了25.5%。纽约梅隆银行(Bank Of New York Mellon Corp)目前持有50,336股该公司股票，价值912,000美元，在此期间又购买了10,240股。法国巴黎银行套利SNC在第三季度收购了Aura Biosciences的新头寸，价值约为105,000美元。道富集团在第三季度增持了16.2%的Aura Biosciences股份。道富银行目前持有298,438股该公司股票，价值5,408,000美元，在此期间又购买了41,692股。先锋集团(Vanguard Group Inc.)在第三季度增持了Aura Biosciences 39.2%的股份。先锋集团目前持有605,884股该公司股票，价值10,978,000美元，在此期间又购买了170,709股。最后，贝莱德股份有限公司在第三季度增持了14.3%的奥拉生物科技股份。贝莱德股份有限公司在此期间增持了126,732股，目前持有1,013,455股该公司股票，价值18,363,000美元。53.96%的股票由机构投资者和对冲基金持有。

Wall Street Analyst Weigh In

华尔街分析师也加入进来

Separately, JMP Securities upped their target price on Aura Biosciences from $26.00 to $30.00 and gave the company a "market outperform" rating in a report on Friday, November 11th.

另外，JMP证券在11月11日(星期五)的一份报告中将Aura Biosciences的目标价从26.00美元上调至30.00美元，并给予该公司“市场表现优于大盘”的评级。

About Aura Biosciences

关于奥拉生物科学公司

(Get Rating)

(获取评级)

Aura Biosciences, Inc operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma.

Aura Biosciences，Inc.是一家开发癌症治疗方法的生物技术公司。该公司开发病毒样药物结合物(VDC)技术平台，用于治疗眼科和泌尿外科肿瘤学中高度未得到满足的肿瘤。它开发了AU-011，一种治疗原发脉络膜黑色素瘤的VDC候选药物。

Featured Stories

专题报道

  • Get a free copy of the StockNews.com research report on Aura Biosciences (AURA)
  • MarketBeat: Week in Review 12/12 – 12/16
  • Which Two Bluechip Tech Companies Have Raised Their Guidance?
  • Should You Worry About Elon Musk Selling His Tesla Shares?
  • Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
  • This is no Time to Buy Lennar but the Time is Coming
  • 免费获取StockNews.com关于AURA生物科学的研究报告(AURA)
  • MarketBeat：回顾一周12/12-12/16
  • 哪两家蓝筹科技公司提高了他们的指引？
  • 你应该担心埃隆·马斯克出售他持有的特斯拉股票吗？
  • 拖拉机库存能否突破杯柄收购点？
  • 现在不是购买Lennar的时候，但时机即将到来

Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

接受《奥拉生物科学日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Aura Biosciences和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发